Multiple sclerosis: Looking beyond autoimmunity

Journal of the Royal Society of Medicine

Volumn 98, Issue 7, 2005, Pages 303-306

  Chaudhuri, Abhijit ^a   Behan, Peter O ^b  

^a Essex Centre for Regional Neurosciences   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; MINOCYCLINE; OMEGA 3 FATTY ACID; UBIDECARENONE; VITAMIN D;

AUTOIMMUNITY; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; INFECTIOUS MONONUCLEOSIS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; VIRUS INFECTION; ACUTE DISEASE; ANIMAL; ARTICLE; BRAIN; DIET SUPPLEMENTATION; DISEASE MODEL; FEMALE; IMMUNOLOGY; MALE; PATHOLOGY; SMOKING; T LYMPHOCYTE;

ACUTE DISEASE; ANIMALS; BRAIN; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; SMOKING; T-LYMPHOCYTES; VITAMIN D;

EID: 22244437937     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.98.7.303     Document Type: Review

References (30)

1. Thomas L. Falsity and failure. In: Late Night Thoughts on Listening to Mahler's Ninth Symphony. New York: Penguin Books, 1995:113
2. Behan PO, Chaudhuri A, Roep BO. The pathogenesis of multiple sclerosis revisited. J R Coll Physicians Edinb 2002;32:244-65
3. Weiner HL. Multiple sclerosis is an inflammatory, T-cell mediated autoimmune disease. Arch Neurol 2004;61:1613-15
4. Chaudhuri A, Behan PO. Multiple sclerosis is not an autoimmune disease. Arch Neurol 2004;61:1610-12
5. Ebers GC, Sandovnick AD, Dyment DA, Yee JML, Wilier CJ, Risch N. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004;363:1773-4
6. Lumsden C. The neuropathology of multiple sclerosis. In: Bruyn GW, Vinken P, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier, 1970:217-309
7. Dalton CM, Chard CT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-7
8. Adams RD. A comparison of the morphology of the human demyelinative diseases and experimental 'allergic' encephalomyelitis. In: Kies MW, Alvord EC Jr, eds. "Allergic" Encephalomyelitis. Washington: Charles C Thomas, 1959:183-209
9. Behan PO, Geshwind N, Lamarche JB, et al. Delayed hypersensitivity to encephalitogenic protein in disseminated encephalitis. Lancet 1968;ii:1009-12
10. Behan PO, Kies MW, Lisak RP, et al. Immunologic mechanisms in experimental encephalomyelitis in non-human primates. Arch Neurol 1973;29:4-9
11. Ingelse M, Salvi F, Iannucci G, et al. Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. Am J Neuroradiol 2002;23:267-72
12. Graham DI, Behan PO, More IAR. Brain damage complicating septic shock. Acute haemorrhagic leukoencephalitis as a complication of generalised Shwartzman reaction. J Neurol Neurosurgery Psychiatry 1979;42:19-28
13. Lennon VA, Wingerchuck DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12
14. Chaudhuri A, Behan PO. Treatment of multiple sclerosis beyond the NICE guideline. Quart J Med 2005;98:373-8
15. Chaudhuri A. Beta interferon, progressive multiple sclerosis and brain atrophy. Lancet Neurol 2005;4:208-9
16. Kalkers NF, Ameziane N, Boost JCJ, Minnebo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis. Rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59:1572-6
17. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for pathogenesis of demyelination. Ann Neurol 2000;47:707-17
18. Hernan MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A. Multiple sclerosis and age at infection with common viruses. Epidemiology 2001;12:301-6
19. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003;3:131-40
20. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001;154:69-74
21. Ruse T, Nortvedt M, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003;61:1122-4
22. Chaudhuri A. Why we should offer routine supplementation of vitamin D in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses 2005;64:608-18
23. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;13:62:60-5
24. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatry Scand 1960;147(suppl):132-47
25. Landtblom A-M, Flodin U, Soderfeldt B, Wolfson C, Axelson O. Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology 1996;7:429-33
26. Riise T, Moen BE, Kryvik KR. Organic solvents and the risk of multiple sclerosis. Epidemiology 2002;13:718-20
27. Shultz CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003;19:1917-21
28. Calon F, Lim GP, Yang F, et al. Docosahexanoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004;43:633-34
29. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nature Med 2000;6:797-801
30. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol 2003;2:291-8